Loperamide Grapefruit Juice Interaction PK Trial

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Consumer and Personal Products Worldwide
ClinicalTrials.gov Identifier:
NCT00806299
First received: December 9, 2008
Last updated: October 4, 2011
Last verified: October 2011
  Purpose

A 10-day study to determine if grapefruit juice has any effect on how loperamide (Imodium) affects the body and how the body affects loperamide.


Condition Intervention Phase
Drug Interaction
Drug: Loperamide / Red Grapefruit Juice
Drug: Loperamide/ White Grapefruit Juice
Drug: Loperamide / Pink Grapefruit Juice
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: An Open Label, Randomized, Single-dose, Fixed-Sequence Crossover Drug Interaction Study of Loperamide HCL With Grapefruit Juice

Resource links provided by NLM:


Further study details as provided by Johnson & Johnson Consumer and Personal Products Worldwide:

Primary Outcome Measures:
  • Pharmacokinetic parameters [ Time Frame: Blood samples will be collected before dosing (predose) and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 10, 14, 24, 30, 36, and 46 hours following each of the three doses ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Pharmacodynamic Parameter: Urine for Analysis of Cortisol and 6-beta Hydroxycortisol [ Time Frame: 8 PM to about 6 AM prior to each dose administration, Day 1, Day 3 and Day 8 ] [ Designated as safety issue: No ]
  • Pharmacodynamic Parameter: Pupillometry Assessments [ Time Frame: predose (0) and at 2, 4, 6, 8, and 12 hours after dosing on Day 1, Day 3 and Day 8 ] [ Designated as safety issue: No ]
  • Pharmacogenomic Evaluation - Genotype CYP3A4, CYP3A5, and ABCB1 [ Time Frame: pre-dose or post-dose ] [ Designated as safety issue: No ]
  • Safety Assessments will consist of monitoring and recording all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product [ Time Frame: throughout duration of the study (+ 30 days for spontaneously reported SAEs) ] [ Designated as safety issue: No ]

Enrollment: 33
Study Start Date: November 2008
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug (including placebo)
Drug: Loperamide / Red Grapefruit Juice
Fixed sequence of loperamide 4 mg with and without red grapefruit juice
Other Name: Imodium
Experimental: 2
Drug (including placebo)
Drug: Loperamide/ White Grapefruit Juice
Fixed sequence of loperamide 4 mg with and without white grapefruit juice
Other Name: Imodium
Experimental: 3
Drug (including placebo)
Drug: Loperamide / Pink Grapefruit Juice
Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
Other Name: Imodium

Detailed Description:

An open-label, randomized, single-dose, fixed-sequence crossover drug interaction study of loperamide HCl with grapefruit juice. About 33 healthy subjects, about equal numbers of men and women, 18 through 59 years of age, will be enrolled into this 10 day trial. Subjects will be divided into three cohorts of about 11 subjects each. Each cohort will receive red, white or pink grapefruit juice. Subjects will take 4 mg of loperamide on Day 1. They will ingest 8 ounces of grapefruit juice and then 4 mg of loperamide on Day 3. They will ingest 8 ounces of grapefruit juice in the morning and in the evening on Days 5, 6 and 7. On Day 8, subjects will ingest 8 ounces of juice and then 4 mg of loperamide. Blood samples will be collected at at predose (0) and 0.5, 1, 1.5, 32, 3, 4, 5, 6, 7, 10, 14, 24, 30, 36 and 46 hours after dosing on Day 1, Day 3 and Day 8. Pupillometry assessments will be performed at pre-dose (0) and 2, 4, 6, 8, and 12 hours after dosing on Day 1, Day 3 and Day 8. Subjects will collect their urine from about 8 PM to about 6 AM prior to dosing on Day 1, Day 3 and Day 8.

  Eligibility

Ages Eligible for Study:   18 Years to 59 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and/or female subjects between the ages of 18 and 59 years, inclusive
  • No clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, and clinical laboratory tests.
  • Subjects will have a Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs).
  • Are normotensive with sitting blood pressure between the range of 90 - 140 mm Hg systolic and 50 - 90 mm Hg diastolic.
  • Have a heart rate of 50-100 beats per minute (bpm).
  • Have a negative urine drug screen at screening and at check-in to the research unit.
  • If female of child-bearing potential, a negative pregnancy test at screening and at admission to the clinical research unit.
  • Able to sign and date the informed consent document, indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  • Received a thorough explanation of the mandatory pharmacogenomic research component of the study and has signed the separate pharmacogenomic informed consent document.
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Extensive restrictions on the type of food and drink allowed
  • Medical history that precludes inclusion in the trial per protocol
  • History of allergy and/or sensitivity to loperamide HCl
  • History of alcohol consumption that precludes inclusion in the trial per protocol
  • Positive screening test for HIV, Hepatitis B or Hepatitis C
  • Treatment with an investigational drug within 30 days preceding the first dose of study medication
  • Females who are pregnant, nursing, or unwilling or unable to use an acceptable method of nonhormonal contraception as outlined in the protocol
  • Use of prescription or nonprescription drugs, vitamins and dietary supplements within 7 days or 5 half-lives prior to first dose
  • Donated or lost blood or blood products within 3 months of first dose or intention to donate blood or blood products within one month after the last dose
  • History of sensitivity to heparin or heparin-induced thrombocytopenia
  • Unwillingness or inability to comply with the Lifestyle Guidelines listed in the protocol
  • Relationship to persons involved directly with the conduct of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00806299

Locations
United States, North Dakota
Cetero Research
Fargo, North Dakota, United States, 58104
Sponsors and Collaborators
Johnson & Johnson Consumer and Personal Products Worldwide
Investigators
Study Director: Dolly Parasrampuria, PhD McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
  More Information

No publications provided

Responsible Party: Johnson & Johnson Consumer and Personal Products Worldwide
ClinicalTrials.gov Identifier: NCT00806299     History of Changes
Other Study ID Numbers: LOPDIR1007
Study First Received: December 9, 2008
Last Updated: October 4, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Loperamide
Antidiarrheals
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 28, 2014